A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib Versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated East Asian Patients With Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
Category & Conditions: Cancer
Medicine: XALKORI®(CRIZOTINIB)
ClinicalTrials.gov Identifier (NCT): NCT01639001
Protocol ID: A8081029
PrintDownloadOpen Plain Language Summary Result: Click here